Utility of Molecular and Structural Brain Imaging to Predict Progression from MCI to Dementia
This project compares three neuroimaging biomarkers to predict progression to dementia in subjects with mild cognitive impairment (MCI). Eighty-eight subjects with MCI and 40 healthy controls (HCs) were recruited. Subjects had a 3T magnetic resonance imaging (MRI) scan, and two positron emission tomography (PET) scans, one with Pittsburgh compound B ([11C]PIB) and one with fluorodeoxyglucose ([18F]FDG). MCI subjects were followed for up to 4 years and progression to dementia was assessed on an annual basis. MCI subjects had higher [11C]PIB binding potential (BPND) than HCs in multiple brain regions, and lower hippocampus volumes. [11C]PIB BPND, [18F]FDG standard uptake value ratio (SUVR) and hippocampus volume were associated with time to progression to dementia using a Cox proportional hazards model.
- Lan et al. - 2017 - Utility of Molecular and Structural Brain Imaging .pdf application/pdf 389 KB Download File
Also Published In
More About This Work
- Academic Units
- Published Here
- February 11, 2022